Therapy Detail

Therapy Name Cisplatin + Pemetrexed
Therapy Description


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Cisplatin Platinol CDDP Chemotherapy - Platinum 6 Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary).
Pemetrexed Alimta LY231514 Chemotherapy - Antimetabolite 10 Alimta (pemetrexed) is an antifolate, which inhibits thymidylate synthase (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT03800134 Phase III Cisplatin + Durvalumab + Gemcitabine Paclitaxel + Carboplatin Cisplatin + Pemetrexed Carboplatin + Pemetrexed Carboplatin + Durvalumab + Pemetrexed Carboplatin + Durvalumab + Paclitaxel Cisplatin + Durvalumab + Pemetrexed Gemcitabine + Cisplatin A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer Recruiting
NCT02542293 Phase III Gemcitabine + Cisplatin Carboplatin + Gemcitabine Durvalumab + Tremelimumab Paclitaxel + Carboplatin Cisplatin + Pemetrexed Carboplatin + Pemetrexed Study of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE). Active, not recruiting
NCT01907100 Phase III Cisplatin + Pemetrexed Nintedanib Nintedanib (BIBF 1120) in Mesothelioma Completed
NCT01868022 Phase I Docetaxel Cisplatin + Pemetrexed GSK3052230 Paclitaxel + Carboplatin Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling Completed
NCT03425643 Phase III Cisplatin + Pemetrexed Cisplatin + Gemcitabine + Pembrolizumab Pembrolizumab Cisplatin + Pembrolizumab + Pemetrexed Gemcitabine + Cisplatin Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) Recruiting
NCT03322566 Phase III Epacadostat + Pembrolizumab Paclitaxel + Carboplatin Cisplatin + Pemetrexed Carboplatin + Pemetrexed Pembrolizumab Plus Epacadostat Alone or With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer Active, not recruiting
NCT02337530 Phase II Selumetinib Cisplatin + Pemetrexed Selumetinib in Patients Receiving Pemetrexed and Cisplatin in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting
NCT03840902 Phase II Paclitaxel + Carboplatin M7824 Cisplatin + Etoposide Durvalumab Cisplatin + Etoposide + M7824 Carboplatin + M7824 + Paclitaxel Cisplatin + M7824 + Pemetrexed Cisplatin + Pemetrexed M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) Not yet recruiting
NCT03164616 Phase III Durvalumab + Tremelimumab Cisplatin + Pemetrexed Carboplatin + Pemetrexed Gemcitabine + Cisplatin Carboplatin + Gemcitabine Durvalumab Carboplatin + nab-paclitaxel Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON) Recruiting
NCT02119650 Phase II Ruxolitinib + Cisplatin + Pemetrexed Cisplatin + Pemetrexed Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer Terminated
NCT02784171 Phase II Cisplatin + Pemetrexed Pembrolizumab Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma Recruiting
NCT02707666 Phase I Pembrolizumab Cisplatin + Pemetrexed A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma Recruiting
NCT02468661 Phase Ib/II Capmatinib Erlotinib Cisplatin + Pemetrexed Carboplatin + Pemetrexed A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification Recruiting
NCT03003962 Phase III Durvalumab Gemcitabine + Cisplatin Carboplatin + Gemcitabine Carboplatin + Pemetrexed Cisplatin + Pemetrexed Paclitaxel + Carboplatin Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer Active, not recruiting
NCT02357147 Phase II Cisplatin + Pemetrexed Amatuximab Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM). (ARTEMIS) Terminated